Abstract 424P
Background
Radiotherapy is a primary or an adjuvant treatment for most brain tumor patients for better tumors control and prolong survival [1]. However, cranial irradiation may cause damages to hippocampus (plural: hippocampi), which may induce dementia after they recovered from the disease [2]. To minimise radiation dose to hippocampus becomes a new trend in radiation therapy [3], [4]. This study is to investigate whether traditional coplanar VMAT (CO-VMAT) or proposed non-coplanar VMAT (NC-VMAT) is dosimetrically superior for brain tumor radiotherapy treatment in view of hippocampus sparing.
Methods
Both CO-VMAT plan and NC-VMAT plan were generated for 16 brain tumor patients (Glioblastoma: 11, Meningioma: 5) using Varian Eclipse planning system version 15.6. The prescription was to give 54 Gy to PTV in 30 fractions. Dose constraints applied for plan optimization were benchmarked against Radiation Therapy Oncology Group (RTOG). In the CO-VMAT plans, there were 1 full arc (179°-181°) and 2 half arcs. The couch angle for all arcs were 0°. For cases with PTV located at the left side of the brain, the gantry angle for the 2 half arcs were set from 0°to 179° and 179° to 0°. While for cases with PTV on the right side of the brain, the gantry angle of the 2 half arcs were set from 0° to 181°and 181°to 0°. In the NC-VMAT plans, all setting were the same as CO-VMAT plans, except that the couch angle for the 2 half arcs was at 315° for PTV located at the left side of the brain, and 45° for PTV located on the right side of the brain.
Results
Homogeneity index, conformation number, dose to other organs at risk and ipsilateral hippocampus were similar in CO-VMAT and NC-VMAT plans. The maximum dose (D-MaxCH) received by contralateral hippocampus in NC-VMAT is 4Gy lower (p=0.049) than that of the CO-VMAT. The dose received by 40 % of the contralateral hippocampus (D40%CH) in NC-VMAT is 1.46Gy (p=0.003) lower than that of the CO-VMAT. The mean D-MaxCH and mean D40%CH were reduced by 23% and 23.5% respectively in NC-VMAT plans when compared with CO-VMAT.
Conclusions
The NC-VMAT is able to minimize radiation dose to contralateral hippocampus while maintaining good plan quality. The NC-VMAT approach may help to consolidate the development of a new standard of care for brain tumor patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tung Wah College.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
104P - Safety and efficacy of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: A randomised, double-blind phase III study
Presenter: Shukui Qin
Session: e-Poster Display Session
105P - Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study
Presenter: Tsai-Sheng Yang
Session: e-Poster Display Session
106P - Efficacy and tolerability of capecitabine and mitomycin-C based concurrent radiotherapy in patients with anal canal cancer
Presenter: Prabhat Bhargava
Session: e-Poster Display Session
107P - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, open-label, early-access PRECONNECT study
Presenter: Timothy Price
Session: e-Poster Display Session
108P - Comparative analysis of two-stage hepatectomy and enhanced one-stage hepatectomy in the setting of bilobar colorectal liver metastases
Presenter: Hayk Torgomyan
Session: e-Poster Display Session
109P - Efficacy and safety of biweekly or triweekly XELOX regimen for adjuvant chemotherapy of colorectal cancer
Presenter: hangyu zhang
Session: e-Poster Display Session
110P - Analysis for stereotactic body radiotherapy (SBRT) effect for colorectal liver metastases
Presenter: Wei Zou
Session: e-Poster Display Session
111P - A meta-analysis study on safety and effectiveness comparison between FOLFOX and XELOX regiments on advanced stage colorectal cancer
Presenter: Ida Bagus Budhi
Session: e-Poster Display Session
112P - Pembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: Asia subgroup results of the phase III KEYNOTE-177 study
Presenter: Takayuki Yoshino
Session: e-Poster Display Session
122P - Nomogram to predict short-term effect of radiotherapy based on pre/post-treatment inflammatory biomarkers and their dynamic changes in esophageal squamous cell carcinoma
Presenter: Shuai Liang
Session: e-Poster Display Session